Stockscreener 앱 받기
1.41
1.08%
0.015
전일 마감가:
$1.395
열려 있는:
$1.41
하루 거래량:
1.56M
Relative Volume:
1.07
시가총액:
$99.69M
수익:
-
순이익/손실:
$-144.01M
주가수익비율:
-0.3516
EPS:
-4.01
순현금흐름:
$-113.02M
1주 성능:
-0.70%
1개월 성능:
+2.92%
6개월 성능:
-26.18%
1년 성능:
-65.27%
1일 변동 폭
$1.31
$1.4402
1주일 범위
$1.31
$1.66
52주 변동 폭
$0.8719
$4.59
바이오미아 퓨전 Stock (BMEA) Company Profile
명칭
Biomea Fusion Inc
전화
(650) 980-9099
주소
1599 INDUSTRIAL ROAD, SAN CARLOS
BMEA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.41 | 98.63M | 0 | -144.01M | -113.02M | -4.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
바이오미아 퓨전 Stock (BMEA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-13 | 개시 | Rodman & Renshaw | Buy |
| 2025-08-28 | 개시 | Jefferies | Buy |
| 2025-06-03 | 재개 | Piper Sandler | Overweight |
| 2024-10-09 | 개시 | Edward Jones | Buy |
| 2024-09-27 | 업그레이드 | Rodman & Renshaw | Neutral → Buy |
| 2024-09-27 | 업그레이드 | Truist | Hold → Buy |
| 2024-08-29 | 개시 | CapitalOne | Overweight |
| 2024-06-11 | 다운그레이드 | Truist | Buy → Hold |
| 2024-06-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-04-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-02-06 | 개시 | Truist | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-06-26 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-05-12 | 개시 | Barclays | Overweight |
| 2023-03-29 | 재확인 | Oppenheimer | Outperform |
| 2023-03-28 | 재확인 | H.C. Wainwright | Buy |
| 2023-02-24 | 개시 | Citigroup | Buy |
| 2022-06-02 | 재개 | H.C. Wainwright | Buy |
| 2022-01-12 | 개시 | H.C. Wainwright | Buy |
| 2021-12-17 | 개시 | Oppenheimer | Outperform |
| 2021-05-11 | 개시 | JP Morgan | Overweight |
| 2021-05-11 | 개시 | Jefferies | Buy |
| 2021-05-11 | 개시 | Piper Sandler | Overweight |
모두보기
바이오미아 퓨전 주식(BMEA)의 최신 뉴스
Biomea Fusion Spotlights Diabetes, Obesity Pipeline at JPMorgan Conference, Sets 2026 Milestones - Yahoo Finance
BMEA: Durable A1C reduction and advancing weight loss studies highlight strong clinical momentum - TradingView — Track All Markets
Biomea Fusion Highlights Diabetes Pipeline at JPM Conference - TipRanks
Biomea Fusion, Inc. Updates on Icovamenib Clinical Progress - TradingView — Track All Markets
Rodman & Renshaw Initiates Coverage on Biomea Fusion (NASDAQ:BMEA) - MarketBeat
Rodman & Renshaw initiates Biomea Fusion stock with Buy rating By Investing.com - Investing.com Nigeria
Rodman & Renshaw initiates Biomea Fusion stock with Buy rating - Investing.com
BMEA: Today's Analyst Rating and Price Target Update | BMEA Stoc - GuruFocus
Biomea Fusion (NASDAQ:BMEA) Given Buy Rating at D. Boral Capital - MarketBeat
Published on: 2026-01-13 19:04:12 - Bộ Nội Vụ
Biomea Fusion outlines 2026 diabetes and obesity drug development plans By Investing.com - Investing.com Nigeria
Biomea Fusion outlines 2026 diabetes and obesity drug development plans - Investing.com
Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones - The Manila Times
Experimental pills for diabetes and obesity line up key 2026 tests - Stock Titan
Biomea Fusion launches public offering of stock and warrants; shares down 23% - MSN
Is Biomea Fusion Inc. stock near bottom after decline2025 Market Outlook & AI Driven Stock Reports - ulpravda.ru
Stop Loss: Is Biomea Fusion Inc. stock near bottom after declineDollar Strength & Advanced Swing Trade Entry Alerts - Улправда
Will Biomea Fusion Inc. stock return to pre crisis levels2026 world cup usa national team round of 16 key players build up play expert forecast preview - ulpravda.ru
Biomea Fusion looks to major milestones in 2026 - Traders Union
Biomea Fusion downgraded to Underweight from Neutral at JPMorgan - MSN
Biomea Fusion Inc. (BMEA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Biomea Fusion explores challenges of insulin therapy - Traders Union
Can Biomea Fusion Inc. stock outperform in 2025 bull marketCEO Change & Detailed Earnings Play Strategies - Улправда
Published on: 2025-12-20 18:19:39 - Улправда
How interest rate cuts could boost Biomea Fusion Inc. stockWeekly Stock Recap & Daily Momentum Trading Reports - Улправда
Published on: 2025-12-20 15:52:57 - Улправда
Will Biomea Fusion Inc. stock split attract more investors2025 Technical Overview & Technical Entry and Exit Alerts - DonanımHaber
Published on: 2025-12-19 02:18:12 - Улправда
Aug Closing: Will Biomea Fusion Inc. stock outperform growth indexesJuly 2025 Action & Risk Controlled Swing Alerts - Улправда
Gap Down: Can Biomea Fusion Inc. stock outperform in 2025 bull market - Улправда
Biomea Fusion, Inc.(NasdaqGS: BMEA) dropped from NASDAQ Biotechnology Index - marketscreener.com
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Biomea Fusion presents COVALENT-111 study results at WCIRDC - MSN
Insider Buying: Biomea Fusion (NASDAQ:BMEA) Insider Acquires 30,000 Shares of Stock - MarketBeat
Biomea Fusion Director Rainer M Erdtmann Acquires 30,000 Shares - TradingView — Track All Markets
[Form 4] Biomea Fusion, Inc. Insider Trading Activity - Stock Titan
JANUS HENDERSON GROUP PLC Acquires Significant Stake in Biomea F - GuruFocus
Interim CEO & Director of Biomea Fusion Michael J. Hitchcock Buys 667% More Shares - simplywall.st
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025 - The Manila Times
Biomea Fusion Highlights the Future of Menin Inhibitors and Icovamenib in Interview with Dr. Ralph DeFronzo at WCIRDC 2025 - Quiver Quantitative
Biomea Fusion (Nasdaq: BMEA) features KOL talk on menin, icovamenib at WCIRDC 2025 - Stock Titan
Biomea Fusion : WCIRDC 2025 COVALENT 111 Week 52 final Oral Presentation - marketscreener.com
Is Biomea Fusion Inc a good long term investmentEarnings Revision Updates & High Profit Market Growth - earlytimes.in
Biomea Fusion reports durable effects of diabetes drug 9 months after dosing - Investing.com Nigeria
Biomea Fusion (BMEA) Stock Jumps on Durable Diabetes Drug Data: Outlook, Analyst Targets and Key Risks as of December 5, 2025 - ts2.tech
Biomea Fusion Showcases Durable Benefits Of Menin Inhibitor In Type-2 Diabetes - RTTNews
Biomea Fusion stock soars after durable diabetes treatment results By Investing.com - Investing.com Nigeria
Biomea Fusion stock soars after durable diabetes treatment results - Investing.com
바이오미아 퓨전 (BMEA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):